Timolol Maleate

This page contains recent news articles, when available, and an overview of Timolol Maleate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Timolol Maleate (when available)

Pharmacology and use:
Similar to propranolol and nadolol, timolol is a nonselective, beta-adrenergic receptor antagonist. Timolol does not demonstrate appreciable intrinsic sympathomimetic or membrane-stabilizing activities but possesses a relatively high degree of lipid solubility and is subject to first-pass metabolism by the liver. For the treatment of hypertension, angina pectoris, cardiac arrhythmias, migraine and for the reduction of mortality following myocardial infarction. Ophthalmic solutions of timolol are used in the treatment of glaucoma to reduce intraocular pressure.

Mechanism Of Action:
Like propranolol and nadolol, timolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle and beta(2)-receptors in the bronchial and vascular smooth muscle. Beta(1)-receptor blockade results in a decrease in resting and exercise heart rate and cardiac output, a decrease in both systolic and diastolic blood pressure, and, possibly, a reduction in reflex orthostatic hypotension. Beta(2)-blockade results in an increase in peripheral vascular resistance. The exact mechanism whereby timolol reduces ocular pressure is still not known. The most likely action is by decreasing the secretion of aqueous humor.

News Articles on Timolol

Othera files investigational new drug application for novel ...  -  Aug 1, 2008
In preclinical animal studies, OT-730 was comparable to timolol maleate in terms of IOP-lowering efficacy and had better systemic safety, according to a OSN SuperSite (subscription),

FDC spurts on buy back plan  -  Aug 4, 2008
In May 2008, FDC received USFDA approval for its abbreviated new drug application for Timolol Maleate ophthalmic solution. FDC’s net profit surged 53.3% to NDTV.com,

Othera files IND application for glaucoma drug  -  Aug 1, 2008
Subjects will be randomized to placebo or 0.5% timolol maleate or 0.75% OT-730. OT-730 is a novel, internally developed next generation topical beta-blocker Pharmaceutical Business Review

Sandoz Eye Solutions Recalled in Canada  -  Jul 21, 2008
Exposure to excess timolol maleate could cause users to experience dry eye, eye irritation, inflammation of the eyelids and/or cornea, drooping of the upper Newsinferno.com,

Sandoz Recalls Eye Drug in Canada  -  Jul 28, 2008
The eyedrops are the generic equivalent of Merck’s Timoptic (timolol maleate) and are used to treat increased intraocular pressure and glaucoma. FDA news (subscription),

Prescription eye drops recalled due to risk of adverse effects  -  Jul 25, 2008
The active ingredient is timolol maleate. Potential adverse events may include red eye, eye irritation, inflammation of the eyelids and-or cornea, The Canadian Press,

All Lots of Sandoz Timolol Ophthalmic Solution 0.25% and 0.5% Recalled  -  Jul 25, 2008
There have been reports of inadvertent overdosage with timolol maleate ophthalmic resulting in systemic effects similar to those seen with systemic Lawyers and Settlements

Health Canada issues warning about timolol ophthalmic solution in ...  -  Jul 22, 2008
...events that could occur because some bottles may contain more timolol maleate than indicated on the label, the agency announced in a press release. OSN SuperSite (subscription),

Allergan reports 20.1% rise in second-quarter product sales  -  Aug 1, 2008
Alphagan P (brimonidine tartrate 0.15%), Alphagan (brimonidine tartrate) and Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) sales totaled OSN SuperSite (subscription),

Sandoz Timolol Ophthalmic Solution Recalled Due to Potential ...  -  Jul 18, 2008
...may contain more of the active ingredient (timolol maleate) than indicated on the label, exposing patients to an increased risk of adverse events. DG News

衛生署說明有關加拿大回收Sandoz Timolol Ophthalmic Solution 0.25 ...  -  Jul 23, 2008
Timolol Ophthalmic Solution 0.25% �?�0.5%，因為�?些藥瓶中，所�?�有效�?分timolol maleate 我的E政府,

US FDA nod for new drug fails to boost FDC  -  Jul 2, 2008
In May 2008, FDC received US Food & Drug Administration approval for its abbreviated new drug application for Timolol Maleate ophthalmic solution. NDTV.com,

FDC Wins Approval for Ciprofloxacin Ophthalmic Solution  -  Jul 3, 2008
The company has recently received approval for Timolol maleate ophthalmic solution. Another abbreviated new drug application Ofloxacin ophthalmic solution RedOrbit,

FDC Obtains US FDA Approval For Its Ciprofloxacin Opthalmic Solution  -  Jul 1, 2008
The company stated that it had recently received approval for Timolol Maleate Ophthalmic Solutio and another ANDA Ofloxacin Ophthalmic Solution is in the RTT News,

Eye problems worsen a bad streak for Jenne  -  Jun 9, 2008
Hardy, the suit says, prescribed timolol maleate -- a beta-blocker used to treat migraine headaches. The suit says another doctor correctly diagnosed MiamiHerald.com,

FDC receives nod from USFDA for Ciprofloxacin solution  -  Jul 2, 2008
It also manufactures bulk drugs, formulations and food products Recently, the company ( FDC) had received nod for Timolol Maleate Ophthalmic Solution. TopNews,

FDC gets USFDA nod for antibiotic drug  -  Jul 2, 2008
The company had recently received approval for Timolol Maleate Ophthalmic Solution. "Another ANDA Ofloxacin Ophthalmic Solution is in the final stages of Economic Times,

Bimatoprost / Timolol Fixed Combination Therapy Demonstrates ...  -  02 Jun 2008
...to receive Ganfort(R) or Xalacom(R) for a 12-week period after a 6-week run-in period on timolol maleate 0.5% (one drop in each eye twice each day). FOXBusiness

FDC's Timolol Maleate receives nod from US FDA  -  May 11, 2008
FDC Ltd has announced that the Company has received approval from the US FDA for its Abbreviated New Drug Application (ANDA), Timolol Maleate Ophthalmic Equity Bulls,

FDC receives USFDA nod for Timolol Maleate Opthalmic Solutions  -  May 9, 2008
Pharma company FDC Ltd today said it has received US Food and Drug Administration's nod for abbreviated new drug application 'Timolol Maleate Opthalmic Trading Markets (press release),

FDC gets US-FDA approval for its Timolol Maleate Ophthalmic Solution  -  May 7, 2008
Timolol Maleate Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle TopNews,

FDC gets USFDA nod for timolol maleate eye drops  -  May 6, 2008
FDC has received the US Food and Drug Administration (USFDA) approval for its timolol maleate eye solution. FDC is engaged in bulk drugs, formulations and Myiris.com,

India's FDC says gets US FDA approval for glaucoma treatment drug  -  May 9, 2008
...(FDA) approval for its Abbreviated New Drug Application (ANDA) Timolol Maleate Ophthalmic Solution, used as a primary line of treatment for glaucoma. Forbes,

Ista conducting strategic review, may consider merger or buyout ...  -  May 14, 2008
First-quarter revenue from sales of Istalol (timolol maleate 0.5%) rose 23% to $2.7 million, while revenues from Vitrase (hyaluronidase) sales declined 10% OSN SuperSite (subscription),

Allergan reports 23% rise in first-quarter total product net sales  -  May 8, 2008
Alphagan P (brimonidine tartrate 0.15%), Alphagan (brimonidine tartrate) and Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) sales totaled $99.5 OSN SuperSite (subscription),

Glaucoma - Tentative Approval For Dorzolamide Hydrochloride With ...  -  Apr 14, 2008
Hi-Tech's dorzolamide hydrochloride with timolol maleate ophthalmic solution is the generic equivalent of Merck's Cosopt® and is indicated for the treatment Medical News Today (press release),

Hi-Tech Pharmacal announces receipt of tentative approval for ...  -  Apr 11, 2008
The company's dorzolamide hydrochloride with timolol maleate ophthalmic solution is the generic version of Merck's Cosopt. Merck's Cosopt had sales of Trading Markets (press release),

Hi-Tech Pharmacal receives tentative FDA approval for generic ...  -  Apr 11, 2008
AMITYVILLE, NY — Hi-Tech Pharmacal's abbreviated new drug application for dorzolamide hydrochloride-timolol maleate ophthalmic solution has received OSN SuperSite (subscription),

Hi-Tech Pharmacal rises after FDA oks company's ANDA for generic ...  -  Apr 10, 2008
...had granted tentative approval for the Abbreviated New Drug Application for its dorzolamide hydrochloride with timolol maleate ophthalmic solution. CNNMoney.com

Link found between glaucoma and cardiovascular death in blacks  -  Apr 8, 2008
...diagnosed with or treated for open angle glaucoma; and 91 percent higher in those who'd been treated with a beta blocker drug called timolol maleate. Asbury Park Press,

Treated open-angle glaucoma and ocular hypertension associated ...  -  12 Mar 2008
Treatment with timolol maleate was particularly problematic, with use of the beta blocker associated with a 70% increased risk of death and a 91% increased TheHeart.Org,

Glaucoma Linked to Cardiovascular Mortality in Black Patients  -  12 Mar 2008
...or treated glaucoma, relative risk 1.38 (95% CI 0.97 to 1.98, P=0.07) and was 91% higher with treatment involving timolol maleate (RR 1.91, P=0.04). MedPage Today,

Timolol may reduce post-phaco IOP increases in patients with ...  -  Jan 30, 2008
Investigators randomly assigned patients to receive one drop of either timolol maleate 0.5% or no treatment immediately after surgery, according to the OSN SuperSite (subscription),

Allergan Reports Fourth Quarter Operating Results  -  Jan 30, 2008
On October 31, 2007, Allergan announced that the US Food and Drug Administration (FDA) approved COMBIGAN(TM) (brimonidine tartrate/timolol maleate PharmaLive.com (press release),

Allergan, Inc. Receives FDA Approval for COMBIGAN ™ (brimonidine ...  -  Oct 31, 2007
The IOP-lowering of COMBIGAN ™ ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate Business Wire (press release),

Combigan Drops Approved for Glaucoma  -  Oct 31, 2007
WEDNESDAY, Oct. 31 (healthday News) -- The US Food and Drug Administration has approved Combigan eye drops (brimonidine tartrate/timolol maleate ophthalmic U.S. News & World Report,

Allergan Wins FDA Approval For Alpha Adrenergic Receptor Agonist ...  -  Oct 31, 2007
...on Wednesday said that the US Food and Drug Administration approved Combigan or brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, Trading Markets (press release),

Allergan granted FDA approval for combination glaucoma medication  -  Oct 31, 2007
Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor. OSN SuperSite (subscription),

FDA Approves Combigan, New Glaucoma Drug  -  Oct 31, 2007
Inc has announced that the US Food and Drug Administration has approved its new glaucoma combo drug Combigan (brimonidine tartrate / timolol maleate). MedHeadlines,

Ista reports 92% increase in third quarter revenue  -  Nov 1, 2007
117% to $11.3 million, Istalol (timolol maleate 0.5%) sales increased 43% to $3 million and Vitrase (hyaluronidase) sales increased 67% to $1.5 million. OSN SuperSite (subscription),

Allergan reports $978.7 million in third-quarter product sales  -  Nov 6, 2007
Alphagan P (brimonidine tartrate 0.15%) and Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) sales increased 12.2% to $89.8 million, OSN SuperSite (subscription),

Allergan Reports Third Quarter Operating Results  -  Nov 6, 2007
On October 31, 2007, Allergan announced that the US Food and Drug Administration approved COMBIGAN(TM) (brimonidine tartrate/timolol maleate ophthalmic Genetic Engineering News (press release),

Allergan Receives FDA Approval for Combigan  -  Nov 1, 2007
Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2 percent/0.5 percent is an eye drop that reduces elevated intraocular pressure. FDA news (subscription),

Wal-Mart Launches Phase Two of Prescription Program With New $4 ...  -  Sep 27, 2007
Wal-Mart has added 24 new $4 prescriptions -- including timolol maleate (glaucoma), terbinafine (antifungal), carvedilol (cardiac), and three $9 women's CNNMoney.com

Wal-Mart to expand $4 Rx program  -  Sep 27, 2007
Among the prescriptions Wal-Mart has added are timolol maleate (glaucoma), antifungal drugs, cardiac drugs and three $9 womens' medications. Newsday,

Wal-Mart expands $4 generic drugs program  -  Sep 27, 2007
These include timolol maleate (to treat glaucoma), terbinafine (antifungal medication), carvedilol (cardiac medication), and generic birth control for Ortho CNNMoney.com

• Wal-Mart Expands $4 Generic Program  -  Oct 1, 2007
Wal-Mart said it has added 24 new $4 prescriptions – including timolol maleate (glaucoma), terbinafine (antifungal), carvedilol (cardiac), Consumer Affairs

Wal-Mart adds more $4 drugs  -  Sep 28, 2007
Among the drugs added in Wal-Mart's nationwide program are timolol maleate (for glaucoma), terbinafine (antifungal) and carvedilol (cardiac). MiamiHerald.com,

Wal-Mart Expands Discount Drug Program In Georgia  -  Sep 27, 2007
Some of the drugs added to the program include: timolol maleate (glaucoma), terbinafine (antifungal), carvedilol (cardiac), and three $9 women’s medications WSBtv.com,

ISTA reports 91% increase in first quarter revenue  -  Apr 26, 2007
OSN SuperSite (subscription),Revenue from sales of Istalol (timolol maleate 0.5%) increased 29% to total $2.2 million, while revenue from Vitrase (hyaluronidase) sales increased 25% to

Allergan Announces FDA Issues Approvable Letter for Combigan ...  -  Dec 22, 2006
PharmaLive.com (press release),Administration (FDA) issued an approvable letter for COMBIGAN(TM) (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% for the reduction

Allergan Announces FDA Issues Approvable Letter for Combigan ...  -  Dec 22, 2006
PharmaLive.com (press release),Administration (FDA) issued an approvable letter for COMBIGAN(TM) (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% for the reduction

Centron Experiences Unprecedented Growth: Its First Anniversary  Aug 24, 2006
Additionally, Centron was named medical communications agency of record for Combigan? (brimonidine tartrate/timolol maleate), a new product from Allergan. -PharmaLive.com

Allergan Reports Second Quarter Operating Results; Total Product ...  Aug 2, 2006
A fixed combination of bimatoprost 0.03% and timolol maleate 0.5%, GANFORT(R) offers powerful IOP-lowering efficacy comparable to the free combination of these ... -Business Wire

Yale Biomedical Engineers Receive Prestigious Early Career Awards  Jul 17, 2006
Erin Lavik was granted the award for her project "Sustained delivery of timolol maleate for management of elevated IOP for glaucoma," in collaboration with ... -Medical News Today

Allergan Gets FDA Nod For Eye Drop LUMIGAN As First-line Treatment ...  Jun 23, 2006
The company said that GANFORT offers powerful IOP-lowering efficacy compared to the free combination of bimatoprost and timolol maleate and greater efficacy ... -Trading Markets

Study Demonstrates Benefits of Combination Treatment for Glaucoma  May 11, 2006
...clinically significant additional reduction in intraocular pressure (IOP) when treated with Cosopt® (dorzolamide hydrochloride/timolol maleate) alone or when ... - DG News

Committee for Medicinal Products for Human Use Summary of Positive ...  Mar 24, 2006
The active substances of Ganfort are bimatoprost and timolol (as timolol maleate), an antiglaucoma agent (ATC code: SO1ED 51), which contains a combination of ... - PharmaLive.com

CMPH - Initial Marketing Authorisation Applications,Europe ... Feb 24, 2006
...-- Duotrav (travoprost/timolol maleate), Alcon Laboratories. Duotrav is an eye-drops solution, intended for the decrease of intraocular ... - Medical News Today,

European Medicines Agency: Committee for Medicinal Products for ...  Feb 23, 2006
Duotrav (travoprost/timolol maleate), Alcon Laboratories. Duotrav is an eye-drops solution, intended for the decrease of intraocular ... - PharmaLive.com,

Santen Announces Preliminary Results of Overseas Clinical Trials ... Feb 14, 2006
085 in the US and Europe after completing a comprehensive statistical analysis of data from another comparison study versus timolol maleate ophthalmic solution ... - Genetic Engineering News,

Brand Names/Synonyms:
Timolol Maleate is also known by the following brand names and/or synonymsApo-Timol; Apo-Timop; Aquanil; Betim; Betimol; Blocadren; HSDB 6533; Istalol; Novo-Timol; Proflax; Temserin; Tenopt; Tim-Ak; Timacar; Timacor; Timolol; Timolol Base; Timolol Maleate; Timololum [Inn-Latin]; Timopic; Timoptic; Timoptic in Ocudose; Timoptic-Xe; Timoptol

Drug Category:
Timolol Maleate is categorized under the following by the FDA: Antihypertensive Agents; Antiarrhythmic Agents; EENT Drugs; ATC:C07AA06; ATC:S01ED01

Dosage Forms:
DROPS; LIQUID; SOLUTION; SOLUTION (LONG-ACTING); TABLET

Absorption:
Bioavailability is about 60%

Interactions:
-->Interactions for Timolol:

Beta-adrenergic blocking agents: Patients who are receiving a beta-adrenergic blocking agent orally and Timolol GFS should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. Patients should not usually receive two topical ophthalmic beta-adrenergic blocking agents concurrently.

Calcium antagonists: Caution should be used in the co-administration of beta-adrenergic blocking agents, such as Timolol GFS, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, co-administration should be avoided.

ENDOCRINE

Masked symptoms of hypoglycemia in diabetic patients. SPECIAL SENSES

Signs and symptoms of ocular irritation including blepharitis, keratitis, and dry eyes; ptosis; decreased corneal sensitivity; cystoid macular edema; visual disturbances including refractive changes and diplopia; pseudopemphigoid; tinnitus and choroidal detachment following filtration surgery.

UROGENITAL

Retroperitoneal fibrosis, decreased libido, impotence and Peyronieís disease.

The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: Allergic: Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress; Body as a Whole: Extremity pain, decreased exercise tolerance, weight loss; Cardiovascular: Worsening of arterial insufficiency, vasodilatation; Digestive: Gastrointestinal pain, hepatomegaly, vomiting, mesenteric arterial thrombosis, ischemic colitis; Hematologic: Nonthrombocytopenic purpura, thrombocytopenic purpura, agranulocytosis; Endocrine: Hyperglycemia, hypoglycemia; Skin: Pruritus, skin irritation, increased pigmentation, sweating; Musculoskeletal: Arthralgia; Nervous System/Psychiatric: Vertigo, local weakness, diminished concentration, reversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometric tests; Respiratory: Rales, bronchial obstruction; Urogenital: Urination difficulties.

Chemical IUPAC Name:
1-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]-3-tert-butylamino-propan-2-ol

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.